Cimetropium bromide

Cimetropium bromide is a semisynthetic quaternary ammonium compound derived from reacting scopolamine with cyclopropylmethyl bromide. It is used primarily as an antispasmodic agent for the treatment of gastrointestinal disorders such as irritable bowel syndrome. Acting as a potent muscarinic receptor antagonist, it inhibits acetylcholine-mediated contractions in the smooth muscle of the digestive tract, thereby reducing spasms and alleviating abdominal pain. Cimetropium bromide demonstrates efficacy in long-term management of IBS symptoms with a favorable tolerability profile and is generally administered orally. Its peripheral antimuscarinic effects are similar to those of atropine but typically result in fewer or milder central nervous system side effects.
Evidence does not support its use in infantile colic.